Sensorion, le début d’une belle aventure




Sensorion est une société de biotechnologie pionnière au stade clinique dédiée au développement de thérapies innovantes pour restaurer, traiter et prévenir dans le domaine des pertes d’audition. Un produit est en développement clinique de phase 2, le SENS-401 (Arazasétron) dans la perte auditive neurosensorielle soudaine (SSNHL).

Nous avons développé dans nos laboratoires une plateforme unique de R&D pour approfondir notre compréhension de la physiopathologie et de l’étiologie des maladies de l’oreille interne. Cette approche nous permet de sélectionner les meilleures cibles thérapeutiques et mécanismes d’action appropriés pour nos candidats médicaments.

Nous travaillons également sur l’identification de biomarqueurs afin d’améliorer le diagnostic de ces maladies peu ou mal soignées. Sensorion a lancé au second semestre 2019 deux programmes précliniques de thérapie génique visant à corriger des formes monogéniques héréditaires de surdité parmi lesquelles le syndrome de Usher de type 1 et les surdités causées par une mutation du gène codant pour l’Otoferline.

Notre plate-forme de R&D et notre portefeuille de candidats médicaments nous positionnent de manière unique pour améliorer de manière durable la qualité de vie des centaines de milliers de personnes souffrant de désordres de l’oreille interne, un besoin médical largement insatisfait dans le monde aujourd’hui.

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL).

Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates.

The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion has launched in the second half of 2019 two preclinical gene therapy programs aiming at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin.

The Company is uniquely placed through its platforms and pipeline of potential therapeutics to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders; a significant global unmet medical need.




Reporting to the CFO, the Investor Relations & Communication Manager F/M is responsible for strategy, execution and measurement of the company’s Investor Relations and Public Relations strategy and will play a key role in supporting broader communications initiatives.


Main Activities



  • Ensure the drafting and implementation of the Company’s communication strategy 
  • Maintain key Messaging, Writing Style and Q&A documents
  • Communicate complex scientific issues in laymen terms for various communications to various audiences
  • Contribute to enhance the company’s profile as an attractive employer


Investor Relations Strategy

  • Develop strategies and programs to keep the financial community current on company performance, goals and industry dynamics. Ensure the company is appropriately and strategically positioned all stakeholders (analysts, investors, etc.)
  • Maintain existing Investor Relations presentation materials and develop new materials as needed
  • Track and maintain a record of sell-side analysts’ coverage including estimates, ratings, reports and other relevant data
  • Develop and produce reports and presentations for senior management and the Board of Managers
  • Interact with top management to help create, plan and execute investor relations programs that can effectively generate interest and deliver messages to financial audiences
  • Support CEO in advising management teams
  • Draft and edit communications materials including press releases, conference call scripts
  • Participate in the reporting process and in the drafting of earnings releases.
  • Attend investor conferences and accompany management on Roadshows with institutional investors and sell side analysts


Public Relations Strategy


  • Cultivate relationships with media contacts to generate interest in key industry news and research/recommend Public Relations opportunities
  • Send press releases and pitches to select media lists to support Public Relations initiatives
  • Write content for corporate website
  • Develop social media calendar and content
  • Maintain tracker of relevant coverage and generate reports to communicate results/effectiveness of PR efforts.
  • Support corporate communications initiatives




  • Prior Experience:
    • At least 5 years of experience in a similar position
    • Significant experience in a health industry: biotech, pharmaceutical industry, clinical and research organisation, etc.
    • International experience desired.


  • Tongues:
    • Fluent in French & English


  • Soft skills:
    • Stress management
    • Priority management
    • Diplomacy / Collaboration with other members of the Executive Committee
    • Leadership / Impactful communication
    • Professional agility
    • Has demonstrated a real strategic dimension in previous experiences